Why Metabolon?

Quantitation

Mass spectrometry is an inherently semi-quantitative, highly sensitive technology that measures the relative quantity differences of an individual metabolite as expressed by the metabolite’s peak intensity variations in comparative samples. Quantitation can be relative (analyzed relative to a reference sample) or absolute (analyzed using a standard curve method).

Metabolomics Approaches to Normalization

Sample normalization in metabolomics is key to deriving accurate biological insight, but care must be taken because of the diversity of metabolite structures and behaviors. There are different normalization approaches, including methods that adjust:

  1. Based on the signal intensity of the sample, for example, by dividing the intensity value of each feature or peak detected in the sample by the total intensity of the entire sample (total ion count (TIC) normalization);
  2. Based on the individual signal intensity of each metabolite. Examples include 1) dividing the intensity value of each metabolite by its median intensity across the experimental samples or 2) dividing the intensity value of each metabolite by its median intensity in control samples. The control samples represent a QC matrix that ideally is pooled from representative samples of the study population (if this option is not available due to sample limitations or feasibility, Metabolon maintains pooled QC matrices for several different sample types).
Metabolomics Approaches to Normalization
Untargeted Global Metabolomics—Relative Quantitation

Untargeted Global Metabolomics—Relative Quantitation

In untargeted metabolomics, there is no standard method for measuring the total amount of metabolites directly, however, Metabolon has performed extensive analyses supported by publications and found that the abovementioned second approach greatly outperformed other methods.1

“When performing normalization to metabolomics data, it is important that the method appropriately corrects for the systematic variation but preserves the biological variation,” says Greg Michelotti, Senior Director of Scientific and Translational Strategy at Metabolon.

In a 2018 study, we determined the best way to normalize metabolomics data based on analysis of plasma samples obtained from participants in the Insulin Resistance Atherosclerosis Study (IRAS).1 From this cohort, 1,716 samples were analyzed using the Metabolon Global Discovery Panel. Accommodating this many samples required between 13 and 15 instrument runs per arm of the platform. The resulting analysis measured 1,274 metabolites. Untargeted metabolomic profiling was compared to a separate targeted panel for a subset of metabolites representative of multiple biochemical classes. In this study, we showed that the normalization methods that rely on metabolite-specific adjustments significantly outperformed the methods that make adjustments across each sample, such as total ion count (TIC) normalization.

Metabolomics Normalization for Relative Quantitation

In many cases, the sample-based normalizations performed worse than performing no normalization. Correcting by the median batch value from the experimental samples (MED) can work well in various applications: for each metabolite, divide the raw peak areas for a sample by the median of the raw peak areas for all samples in the same instrument batch.

However, suppose one wants to run a very small set and merge it into previous data sets or compare the values in two different data sets. In that case, it is typically better to normalize by bridging control samples (BRDG): for each metabolite, divide the raw peak areas for a given sample by the median of the raw peak areas of the bridging control samples. The main drawback of BRDG is that metabolites that are not present in the bridge samples cannot be normalized.1

Metabolomics Normalization for Relative Quantitation
Targeted Metabolomics—Absolute Quantitation

Targeted Metabolomics—Absolute Quantitation

Targeted metabolomics can take advantage of absolute quantitation since the panel or assay can be optimized for specific compounds. Optimization improves sensitivity and specificity but sacrifices broad analyte coverage. Absolute quantitation means that the metabolites can be quantitated based on a known quantity using the standard curve method. A standard curve or calibration curve is a general method for determining the concentration of a substance in an unknown sample by comparing the unknown to a set of standard samples of known concentration. The quantity of metabolites in a sample is reported as a concentration (eg, 21.5 ng/mL). You may want to use absolute quantitation when you want to compare data over time. This type of quantitation is helpful when your biomarker data extends across various studies and batches or comprises diagnostic test data.

References

1. Wulff, Jacob E., and Matthew W. Mitchell. “A comparison of various normalization methods for LC/MS metabolomics data.” Advances in Bioscience and Biotechnology 9.08 (2018): 339.

See how Metabolon can advance your path to preclinical and clinical insights

Why Metabolon?

Once you see the full value of metabolomics, the only remaining question is who does it best? While many laboratories have metabolite profiling or analytical chemistry capabilities, comprehensive metabolomics technologies are extremely rare. Accurate, unbiased metabolite identification across the entire metabolome introduces signal-to-noise challenges that very few labs are equipped to handle. Also, translating massive quantities of data into actionable information is slow, if not impossible, for most because proper interpretation takes two things that are in short supply: experience and a comprehensive database.

Only Metabolon has all four core metabolomics capabilities

R

Coverage

Ability to interrogate thousands of metabolites across diverse biochemical space, revealing new insights and opportunities

R

Comparability

Ability to integrate the data from different studies into the same dataset, in different geographies, among different patients over time

R

Competency

Ability to inform on proper study design, generate high‐quality data, derive biological insights, and make actionable recommendations

R

Capacity

Ability to process hundreds of thousands of samples quickly and cost‐efficiently to service rapidly growing demand

Partner with Metabolon to access:

R

A library of 5,400+ known metabolites, 2,000 in human plasma, all referenced in the context of biochemical pathways

  • That’s 5x the metabolites of the closest competitor
R

Unparalleled depth and breadth of experience analyzing and interpreting metabolomic data to find meaningful results

  • 10,000+ projects with hundreds of clients
  • 3,500+ publications covering 500 diseases, including numerous peer-reviewed journals such as Cell, Nature and Science
  • Nearly 40 PhDs in data science, molecular biology, and biochemistry

Using our robust platform and visualization tools, our experts are uniquely able to tell you more about your molecule and develop assay panels to help you zero in on the results you need.

Contact Us

Talk with an expert

Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos
Germany

+49 89 99017752

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.